Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – EurekAlert
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
IMAGE: Tina Cascone, M.D., Ph.D.
view more
Credit: MD Anderson Cancer Center
HOUSTON — The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas…
-
Noosa News22 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer
-
General21 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
General22 hours agoPolice say man shot dead in Footscray had charged at officers armed with knife
-
General19 hours agoNew Zealand wants more ‘automated decision-making’ in its welfare system. Could that lead to Robodebt 2.0?